Investor Presentation First Nine Months of 2022
Novo NordiskⓇ
103
Investor presentation First nine months of 2022
Evoke and evoke+ trials are ongoing with expected completion in
2025
evoke and evoke+ trials have been initiated with 1,840 patients in each trial with a total of 3,680 patients
3 mg
7 mg
R
3 mg
7 mg
1:1
8
Week 0
4
14 mg oral semaglutide QD
14 mg oral semaglutide QD
14 mg placebo QD
14 mg placebo QD
+
104
Treatment period
+
Confirmatory
endpoints
Objective
To confirm superiority of oral semaglutide vs
placebo on the change in cognition and function
in people with early Alzheimer's disease
Primary endpoint
Change in the Clinical Dementia
Rating - Sum of Boxes (CDR-SB)
score from baseline to end of 104
weeks of treatment
Inclusion criteria
156
161
Follow-up
•
Early Alzheimer's disease (mild cognitive impairment
or mild dementia)
•
•
Mini-Mental State Examination (MMSE) ≥ 22/30
Age between 55-85 years
evoke+ has at least 20% with small vessel pathology
AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; QD: once-daily.
Note: CDR-SB ratings are utilising in six domains are summed to provide a clinical measure = Sum of Boxes. These are: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care.
CDR-SB Scores range from 0 to 18 with higher scores representing greater impairmentView entire presentation